A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Nave Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Hematologic

A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em

Thyroid

Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination with FOLFOX Plus Bevacizumab as Frontline Treatment in Patients with Metastatic Colorectal Cancer

Multiple Cancer Types

Phase 3 Multicenter, Randomized, Open-label, Active-Controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants with Relapsed or Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Multiple Cancer Types

Expanded Access Protocol for Product which does not conform to the TECELRA (Afamitresgene autoleucel, suspension for intravenous infusion) Commercial Release Specification.

Sarcoma

Neoadjuvant REGN2810 (Cemiplimab) in Cutaneous Basal Cell Carcinoma of the Head and Neck

Head/Neck

A Phase 1a/1b Trial of LY3962673 in Participants with KRAS G12D-Mutant Solid Tumors

Multiple Cancer Types

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma